Septerna, a South San Francisco, CA-based biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), raised $150M in Series B funding.
The round was led by RA Capital Management, with participation from existing investors Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital and Logos Capital, as well as additional new investors Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Driehaus Capital Management, Woodline Partners LP, Soleus Capital, and an additional undisclosed investor. In conjunction with the financing, Jake Simson, Ph.D., partner at RA Capital Management, will join Septerna’s board of directors.
The company intends to use the funds to continue development of its portfolio of novel products targeting well-validated GPCRs, including advancement of its lead program targeting the parathyroid hormone 1 receptor (PTH1R) to clinical proof-of-mechanism, and preclinical advancement of its program targeting thyroid stimulating hormone receptor (TSHR) and other earlier stage assets.
Led by Jeffrey Finer, M.D., Ph.D. and CEO, Septerna is a biotechnology company focused on advancing novel, oral small molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). Its Native Complex™ Platform recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment to rapidly apply new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. The company is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism.
FinSMEs
17/07/2023